Company Filing History:
Years Active: 2010-2012
Title: Jeremie Decalf: Innovator in Infection Treatment
Introduction
Jeremie Decalf is a prominent inventor based in Paris, France. He has made significant contributions to the field of infection treatment, holding 2 patents that focus on innovative methods for assessing and treating infections.
Latest Patents
His latest patents include methods of using sIP-10, CD26 inhibitors, and CXCR3 levels in a sample to assess clearance of infection, response to interferon therapy, and treating chronic infections. The first patent relates to methods for the treatment of infection using CD26 (DPIV) inhibitors. It also involves an antibody that binds to the IP-10 protein and a method for monitoring the necessity of administering a CD26 inhibitor to a patient by evaluating levels of sIP-10, activity of CD26, and/or levels of CXCR3 cells in a sample. The second patent focuses on methods of using sIP-10 to assess HCV clearance and/or response to interferon therapy. This invention evaluates and predicts clinical outcomes in patients by measuring levels of sIP-10 protein expression, as well as therapies using sIP-10 and its fragments.
Career Highlights
Jeremie Decalf is associated with the Institut Pasteur, a renowned research institution known for its contributions to the field of microbiology and infectious diseases. His work at this institution has allowed him to explore innovative solutions for treating infections.
Collaborations
He has collaborated with notable colleagues, including Matthew Albert and Stanislas Pol, to advance research in his field.
Conclusion
Jeremie Decalf's innovative work in infection treatment showcases his dedication to improving patient outcomes through scientific research and invention. His contributions are vital in the ongoing battle against infectious diseases.